HealthDay News — Tagraxofusp appears effective for treating the rare aggressive hematologic cancer blastic plasmacytoid dendritic-cell neoplasm (BPDCN), according to a study published in the April 25 issue of the New England Journal of Medicine.
Naveen Pemmaraju, MD, from the University of Texas MD Anderson Cancer Center in Houston, and colleagues assigned 47 patients with untreated (32 participants) or relapsed (15 participants) BPDCN to receive an intravenous infusion of tagraxofusp (7 µg or 12 µg per kilogram) on days 1 to 5 of each 21-day cycle.
The researchers found that 21 of the 29 previously untreated patients who received a dose of 12 µg per kilogram achieved the primary outcome (complete response and clinical complete response), with an overall response rate of 90%. Half of these patients (45%) went on to undergo stem cell transplantation. Survival rates were 59 and 52% at 18 months and 24 months, respectively. The response rate among the 15 previously treated patients was 67%, and the median overall survival was 8.5 months. Increased levels of alanine aminotransferase (64%) and aspartate aminotransferase (60%), hypoalbuminemia (55%), peripheral edema (51%), and thrombocytopenia (49%) were the most common adverse events. Nearly 1 in 5 patients (19%) reported capillary leak syndrome, which was associated with one death in each of the dose groups.
“We treated patients up to the age of mid-80s, and there was no obvious difference in toxicity by age, which is not the case in standard chemotherapy,” a coauthor said in a statement. “Unlike standard chemotherapy, there doesn’t seem to be a cumulative toxicity with this drug.”
Several authors disclosed financial ties to pharmaceutical companies, including Stemline, which manufactures tagraxofusp and partially funded the study.